Estrella Immunopharma, Inc. (NASDAQ:ESLA – Get Free Report) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 19,100 shares, a growth of 8.5% from the June 30th total of 17,600 shares. Based on an average daily volume of 17,600 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.2% of the shares of the stock are short sold.
Estrella Immunopharma Stock Performance
ESLA stock traded up $0.14 during mid-day trading on Thursday, reaching $1.70. 25,202 shares of the company’s stock were exchanged, compared to its average volume of 59,933. The stock’s 50 day moving average is $1.16 and its 200 day moving average is $1.13. Estrella Immunopharma has a 12-month low of $0.81 and a 12-month high of $33.00.
Estrella Immunopharma (NASDAQ:ESLA – Get Free Report) last announced its earnings results on Tuesday, May 14th. The company reported ($0.01) EPS for the quarter.
Hedge Funds Weigh In On Estrella Immunopharma
About Estrella Immunopharma
Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.
Further Reading
- Five stocks we like better than Estrella Immunopharma
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Industrial Products Stocks Investing
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
- Best Aerospace Stocks Investing
- Analysts Expect At Least 60% Upside In This Fintech
Receive News & Ratings for Estrella Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Estrella Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.